Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis

Mycoses

Volumn 56, Issue 3, 2013, Pages 304-310

  Heinz, Werner J ^a   Egerer, Gerlinde ^b   Lellek, Heinrich ^c   Boehme, Angelika ^d   Greiner, Jochen ^e  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Onkologikum Frankfurt Am Museumsufer   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Aspergillosis; Fungal infections; Posaconazole; Salvage therapy; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL EVALUATION; DESCRIPTIVE RESEARCH; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GERMANY; HUMAN; INVASIVE ASPERGILLOSIS; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIFUNGAL AGENTS; ASPARTATE AMINOTRANSFERASES; ASPERGILLOSIS; DRUG EVALUATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

ASPERGILLUS;

EID: 84876331869     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12023     Document Type: Article

References (20)

1. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009; 52: 197-205.
2. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
3. Katragkou A, Tsikopoulou F, Roilides E, Zaoutis TE. Posaconazole: when and how? The clinician's view. Mycoses 2012; 55: 110-22.
4. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol 2011; 3: 175-91.
5. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009; 18: 1279-95.
6. EMA. Noxafil: EPAR - product information. 2011. 21-11-2011.
7. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie e.V. Invasive Pilzinfektionen-Therapie Leitlinie. 2009. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie e.V. 27-2-2012.
8. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant 2011; 46: 709-18.
9. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
10. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
11. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
12. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
13. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
14. Hachem RY, Langston AA, Graybill Jr. et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 2008; 62: 1386-91.
15. Cornely OA, Maertens J, Bresnik M et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54: e449-55.
16. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007; 9: 89-96.
17. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40: 1684-8.
18. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
19. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
20. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119: 527 e17-24.